Published in Cancer Weekly, June 12th, 2007
"Some of these subsequent changes, which we have termed M3 to Mn, are likely crucial for tumor progression not only in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.